GSK 2190914 / BMS, GSK - LARVOL DELTA

Robotic versus open ventral hernia repair (ROVHR): a randomized controlled trial protocol. (PubMed, Hernia) - P=N/A | "Based existing literature, we designed a randomized trial with a primary endpoint to determine if robotic retromuscular hernia repairs reduce length of in hospital stay by at least 24 h compared to open retromuscular hernia repairs. This study will add high-level of evidence providing evidence-based outcomes for clinical decision making."

Clinical • Clinical protocol • Journal • Gastroenterology • Pain

Chemical burn wounds as a risk factor for gastric cancer: in-silico analyses-experimental research. (PubMed, Ann Med Surg (Lond)) - "Additionally, the current study presented five drugs, including Urokinase, Tenecteplase, DG031, AM103, and Fiboflapon, which can have predicted effects on gastric cancer following chemical burns. According to current in-silicon analyses, ALOX5AP and SERPINB2 are linked genetic keys between gastric chemical burn and cancer. Considering that burn is an environmental factor that leads to the upregulation of the two genes thus, the chemical burn can be related to the incidence of gastric cancer."

Journal • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • Thermal Injury

HSS9007: T-cell engaging immunotherapy in early treatment of B-cell acute lymphoblastic leukemia (B-ALL) (EHA 2024) - "The third presentation, "Novel approaches in pediatric populations" will be covered by Martin Schrappe (DE) which will be followed by a panel discussion on future perspectives together with Nicola Gökbuget (DE). Date of Preparation: May 2024; SC-ELMAC-AMG103-00307"

Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Pediatrics

A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery (clinicaltrials.gov) - P2/3; N=29; Completed; Sponsor: Ottawa Hospital Research Institute; Active, not recruiting -> Completed ; N=60 -> 29

Enrollment change • Trial completion • Biosimilar • Chronic Kidney Disease • Renal Disease

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients (clinicaltrials.gov) - P4; N=87; Completed; Sponsor: M.D. Anderson Cancer Center; Active, not recruiting -> Completed ; Trial primary completion date: Apr 2016 ->Sep 2014

Trial completion • Trial primary completion date • Biosimilar • Oncology • Pancreatic Cancer